Optimal use of existing and new antifungal drugs

Current Opinion in Critical Care

Volumn 7, Issue 4, 2001, Pages 238-241

  Rogers, Thomas R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

CANDIDA ALBICANS; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; INTENSIVE CARE UNIT; MYCOSIS; NEPHROTOXICITY; REVIEW;

ANTIFUNGAL AGENTS; HUMANS; MYCOSES;

EID: 0034837880     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200108000-00005     Document Type: Review

References (42)

1. Epidemiology of nosocomial fungal infections
2. Hospital-acquired candidemia: The attributable mortality and excess length of stay
3. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
4. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness
5. Systemic Candida infection in extremely tow birth weight infants: Short term morbidity and long term neurodevelopmental outcome
6. Four year prospective evaluation of nosocomial bacteremia: Epidemiology, microbiology, and patient outcome
7. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
8. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
9. Candida glabrata fungemia
10. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
11. Therapy of deep fungal infection in haematological malignancy
12. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
13. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
14. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
15. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion
16. Liposomal amphotericin B (Ambisome) in the treatment of neonatal candidiasis in very low birth weight infants
17. A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B
18. A randomised trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
19. Practice guidelines for the treatment of candidiasis
20. Intravascular catheter exchange and duration of candidemia
21. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital
22. Fungal and parasitic infections of the eye
23. Management of deep Candida infection in surgical and intensive care unit patients
24. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients
25. Association of fungal infection and increased mortality in liver transplant recipients
26. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation
27. Resistance of Candida species to fluconazole
28. Effects of fluconasole administration in critically ill patients
29. Candida krusei fungemia. An escalating serious infection in immunocompromised patients
30. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized controlled trials
31. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
32. A multicenter, randomised trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
33. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia: A randomised, double blind, double placebo, multicenter trial comparing itraconazole and amphotericin B
34. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
35. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses
36. Voriconasole versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: A randomised, international, multicenter trial
37. In vitro susceptibilities of Candida blood stream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
38. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
39. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. To amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)
40. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
41. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
42. Multicenter, noncomparative Study to evaluate safety and efficacy of Caspofungin (CAS) in adults with invasive aspegillosis (IA) refractory or intolerant to amphotencin B (lipid AMB) or azoles